tirzepatide patient information leaflet 🚨 Patient Information: Tirzepatide (Mounjaro®) 🚨 Tirzepatide is being offered under the following strict criteria: ✓ You have at least 4 of these 5 conditions – Type 2 Diabetes, Hypertension (high Weight Management Medication - Papworth

[0081] Using MAIDI-TOFMS for detection, the results are shown in figure 2 , MAIDI-TOFMS calculates C 24 h 30 N 6 o 8 Theoretical molecular weight [M+H] + m / z=531.220,[M+Na] + = 553.202, observed: 531.098, 553.081

If there are too many free radicals loose in the body, it can cause damage to your cells, proteins, and even your DNA, which may further lead to dangerous diseases such as diabetes, cancer, and rheumatoid arthritis

days 1 to 30): 1.5 mg orally once a day Dose escalation (days 31 to 60): 4 mg orally once a day Maintenance dose (day 61 and onward): If no additional glycemic control is needed: 4 mg orally once a day If additional glycemic control is needed: 9 mg orally once a day Rybelsus Tablets: Initial dose (initiation phase

Macrophage Polarisation: The process where immune cells (macrophages) change their behaviour